Go Pro
→ You’re skeptical after SpaceX’s IPO, and that’s alright (From Brownstone Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
$5.54
$5.55
$2.61
▼
$5.65
$290.24M1.25376,318 shsN/A
Cybin Inc. stock logo
HELP
Cybin
$12.18
-8.0%		$8.54
$3.76
▼
$14.35
$889.87M0.551.19 million shs1.45 million shs
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
$4.70
-4.1%		$4.36
$3.35
▼
$7.98
$976.24M0.7659,811 shs1.12 million shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$25.75
-0.3%		$25.12
$18.80
▼
$27.66
$1.03B0.27683,442 shs483,552 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
0.00%0.00%0.00%0.00%0.00%
Cybin Inc. stock logo
HELP
Cybin
-2.86%+6.17%+74.21%+190.99%+1,323,999,900.00%
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
+1.66%+5.38%+5.60%-0.61%-6.31%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
-0.27%+8.39%-3.66%+11.24%-1.15%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
$5.54
$5.55
$2.61
▼
$5.65
$290.24M1.25376,318 shsN/A
Cybin Inc. stock logo
HELP
Cybin
$12.18
-8.0%		$8.54
$3.76
▼
$14.35
$889.87M0.551.19 million shs1.45 million shs
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
$4.70
-4.1%		$4.36
$3.35
▼
$7.98
$976.24M0.7659,811 shs1.12 million shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$25.75
-0.3%		$25.12
$18.80
▼
$27.66
$1.03B0.27683,442 shs483,552 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
0.00%0.00%0.00%0.00%0.00%
Cybin Inc. stock logo
HELP
Cybin
-2.86%+6.17%+74.21%+190.99%+1,323,999,900.00%
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
+1.66%+5.38%+5.60%-0.61%-6.31%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
-0.27%+8.39%-3.66%+11.24%-1.15%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
0.00
N/AN/AN/A
Cybin Inc. stock logo
HELP
Cybin
3.00
Buy$48.60299.01% Upside
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
3.10
Buy$15.38227.13% Upside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
2.29
Hold$30.2017.28% Upside

Current Analyst Ratings Breakdown

Latest ALIM, PCRX, IVA, and HELP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
Cybin Inc. stock logo
HELP
Cybin
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$8.00 ➝ $62.00
8/17/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
8/17/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$30.00
8/5/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSector Perform$24.00 ➝ $25.00
8/5/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$32.00 ➝ $33.00
7/27/2026
Cybin Inc. stock logo
HELP
Cybin
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$16.00
7/17/2026
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight
7/1/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$38.00
(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
$99.68M2.91N/AN/A$0.88 per share6.30
Cybin Inc. stock logo
HELP
Cybin
N/AN/AN/AN/A$3.31 per shareN/A
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
$5.07M192.55N/AN/A($0.22) per share-21.36
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$726.41M1.41$3.84 per share6.71$16.86 per share1.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
-$20.13M-$1.57N/A26.38N/A-14.74%-33.70%-9.63%N/A
Cybin Inc. stock logo
HELP
Cybin
-$148M-$3.02N/AN/AN/AN/A-71.78%-64.81%N/A
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
-$400.67MN/AN/AN/AN/AN/AN/AN/A9/25/2026 (Estimated)
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$7.03M$0.3573.5710.73N/A1.96%9.68%5.30%11/5/2026 (Estimated)

Latest ALIM, PCRX, IVA, and HELP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/25/2026Q2 2026
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
-$0.20N/AN/AN/A$4.76 millionN/A
8/14/2026Q1 2027
Cybin Inc. stock logo
HELP
Cybin
-$0.80-$0.91-$0.11-$0.91N/AN/A
8/4/2026Q2 2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.6460$0.73+$0.0840$0.12$191.06 million$192.40 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
N/AN/AN/AN/AN/A
Cybin Inc. stock logo
HELP
Cybin
N/AN/AN/AN/AN/A
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
N/AN/AN/AN/AN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
1.80
2.79
2.62
Cybin Inc. stock logo
HELP
Cybin
N/A
10.97
10.97
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
N/A
3.16
3.16
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.54
5.04
3.94

Institutional Ownership

CompanyInstitutional Ownership
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
99.83%
Cybin Inc. stock logo
HELP
Cybin
17.94%
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
19.06%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
99.73%

Insider Ownership

CompanyInsider Ownership
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
31.40%
Cybin Inc. stock logo
HELP
Cybin
15.00%
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
32.00%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
6.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
15052.39 million35.94 millionNo Data
Cybin Inc. stock logo
HELP
Cybin
5073.06 million62.10 millionN/A
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
100207.71 million141.24 millionNot Optionable
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
72039.86 million37.31 millionOptionable

Recent News About These Companies

PDT Partners LLC Makes New Investment in Pacira BioSciences, Inc. $PCRX
August 27 at 5:21 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-pdt-partners-llc-makes-new-investment-in-pacira-biosciences-inc-pcrx-2026-08-27/
Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) PT at $29.80
August 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30976627
Foster & Motley Inc. Buys New Holdings in Pacira BioSciences, Inc. $PCRX
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-foster-motley-inc-buys-new-holdings-in-pacira-biosciences-inc-pcrx-2026-08-20/
Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares
August 19, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-pcrx-insider-buying-and-selling-2026-08-19/
Rice Hall James & Associates LLC Purchases Shares of 93,396 Pacira BioSciences, Inc. $PCRX
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-rice-hall-james-associates-llc-purchases-shares-of-93396-pacira-biosciences-inc-pcrx-2026-08-19/
Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares of Stock
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pacira-biosciences-nasdaqpcrx-insider-jonathan-slonin-sells-3040-shares-of-stock-2026-08-18/
Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated at Truist Financial
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pacira-biosciences-nasdaqpcrx-coverage-initiated-at-truist-financial-2026-08-17/
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of "Hold" from Brokerages
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pacira-biosciences-inc-nasdaqpcrx-receives-consensus-recommendation-of-hold-from-brokerages-2026-08-17/
Empowered Funds LLC Buys 49,171 Shares of Pacira BioSciences, Inc. $PCRX
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-empowered-funds-llc-buys-49171-shares-of-pacira-biosciences-inc-pcrx-2026-08-17/
Pacira BioSciences (NASDAQ:PCRX) Lowered to "Buy" Rating by Wall Street Zen
August 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pacira-biosciences-nasdaqpcrx-lowered-to-buy-rating-by-wall-street-zen-2026-08-16/
Wedge Capital Management L L P NC Purchases New Stake in Pacira BioSciences, Inc. $PCRX
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wedge-capital-management-l-l-p-nc-purchases-new-stake-in-pacira-biosciences-inc-pcrx-2026-08-14/
Assenagon Asset Management S.A. Acquires Shares of 101,429 Pacira BioSciences, Inc. $PCRX
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-acquires-shares-of-101429-pacira-biosciences-inc-pcrx-2026-08-14/
Equities Analysts Set Expectations for PCRX Q3 Earnings
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/equities-analysts-set-expectations-for-pcrx-q3-earnings-2026-08-12/
HC Wainwright Issues Optimistic Estimate for PCRX Earnings
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-issues-optimistic-estimate-for-pcrx-earnings-2026-08-11/
Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy?
August 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pacira-biosciences-pcrx-quietly-reframing-061005117.html
Hennion & Walsh Asset Management Inc. Buys 48,124 Shares of Pacira BioSciences, Inc. $PCRX
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hennion-walsh-asset-management-inc-buys-48124-shares-of-pacira-biosciences-inc-pcrx-2026-08-10/
Pacira BioSciences (NASDAQ:PCRX) Upgraded by Wall Street Zen to Strong-Buy Rating
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pacira-biosciences-nasdaqpcrx-upgraded-by-wall-street-zen-to-strong-buy-rating-2026-08-08/
Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform
August 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4933647-pacira-biosciences-reimbursement-is-turning-an-old-franchise-into-a-new-growth-platform
Pacira BioSciences (PCRX) Could Be 35% Undervalued On Phase 1 Gene Therapy Progress
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pacira-biosciences-pcrx-could-35-211402733.html
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in ...
August 6, 2026  |  caledonianrecord.comC
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pacira-biosciences-announces-publication-positive-120000262.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
Cleanroom semiconductor fab with advanced wafer fabrication equipment processing silicon wafers, highlighting chip manufacturing industry growth.
Everyone’s Focused on China—But That’s Not ASML’s Biggest Risk
By Dan Schmidt | July 31, 2026
A steak cooks over an open flame on a restaurant grill, with kitchen equipment visible in the background.
Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
By Dan Schmidt | August 15, 2026
Athletic apparel store interior displaying mannequins in activewear, folded clothing, and shoe shelves alongside hanging garment racks.
China’s Athleisure Boom Is Not Lifting Every Brand Equally
By Chris Markoch | August 11, 2026
Curaleaf logo displayed with cannabis leaves and a bud on a reflective surface against a dark green background.
Joint Operations: Curaleaf Makes a Play for Aurora Cannabis
By Jeffrey Neal Johnson | August 14, 2026
Alimera Sciences stock logo

Alimera Sciences NASDAQ:ALIM

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Cybin stock logo

Cybin NASDAQ:HELP

$12.18 -1.06 (-8.01%)
As of 04:00 PM Eastern

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Inventiva stock logo

Inventiva NASDAQ:IVA

$4.70 -0.20 (-4.08%)
As of 04:00 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Pacira BioSciences stock logo

Pacira BioSciences NASDAQ:PCRX

$25.75 -0.08 (-0.31%)
As of 04:00 PM Eastern

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas